Clinical trial · Observational
The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer
The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Detection of Primary Tumor and Axillary Metastasis for Breast Cancer: SUVMax Against to ADC
NCT01942759CI-TRIAL-00014818completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine findings of positron emission tomography and diffusion weighted magnetic resonance in primary lesion and axillary metastasis of breast cancer and compare of two imaging modality in these patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (6)
- label
- Histologic grade
- description
- According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3
- label
- Axillary metastasis
- description
- Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis
- label
- Modified Nottingham prognostic index
- description
- NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3) The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (\>5.4) prognostic groups
- label
- Oestrogen receptor status
- description
- Negative Positive
- label
- Progesterone receptor status
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosis of breast cancer for which surgical intervention is planned Exclusion Criteria: * patients received neoadjuvant chemotherapy * before breast surgery
References
Publications (0)
Data not yet available
No reference posted for this study.